Related Experiment Video
Updated: Jul 1, 2025
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.6K
Updates on Non-Statin LDL-Lowering Therapy.
Amer Abdulla1, Mostafa Shalaby2, Paul Kumfa2
1, 301 University Blvd., JSA 5.106G, Galveston, TX, 77555-0553, USA. ameabdul@utmb.edu.
Current Cardiology Reports
|March 4, 2024
Summary
New non-statin therapies effectively lower low-density lipoprotein (LDL) cholesterol, reducing cardiovascular events. These agents, including ezetimibe and PCSK9 inhibitors, offer safe and effective options for patients needing additional LDL reduction.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of mortality.
- Low-density lipoprotein (LDL) cholesterol is a primary target for ASCVD prevention.
- Statins are first-line therapy, but many patients require additional LDL-lowering strategies.
Purpose of the Study:
- To review current non-statin LDL-lowering therapies.
- To discuss their mechanisms of action, efficacy, and safety.
- To provide clinical practice recommendations for their use.
Main Methods:
- Narrative review of available non-statin LDL-lowering agents.
- Analysis of data from randomized controlled trials and expert consensus.
Main Results:
- Ezetimibe, PCSK9 inhibitors, and bempedoic acid are safe and effective in reducing cardiovascular events.
- Inclisiran shows promise in suppressing PCSK9 and is under clinical investigation.
- Expert consensus supports lower LDL targets and combination therapy for high-risk patients.
Conclusions:
- Non-statin therapies are valuable additions to the LDL-lowering armamentarium.
- These agents enable achievement of lower LDL targets in high-risk individuals.
- Personalized treatment strategies incorporating non-statin agents are crucial for ASCVD prevention.
Keywords:
Bempedoic acidEzetimibeHyperlipidemiaInclisiranLow-density lipoproteinProprotein convertase subtilisin/kexin type 9 inhibitorMore Related Videos
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
661
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
661
01:28Drug Therapy
43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
43
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
636
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
636
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
01:24Rational Dosage Regimen: Maintenance Dose and Loading Dose
4.1K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.1K
01:26Heart Failure Drugs: Inotropic Agents
586
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
586